On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.
about
Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancerFramingham risk score with cardiovascular events in chronic kidney diseaseDiagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic CirrhosisPredicting survival in head and neck squamous cell carcinoma from TP53 mutation.A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival dataValidation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.Assessing risk prediction models using individual participant data from multiple studiesBoosting the concordance index for survival data--a unified framework to derive and evaluate biomarker combinations.Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis.Covariate-adjusted measures of discrimination for survival dataA statistical framework to model the meeting-in-the-middle principle using metabolomic data: application to hepatocellular carcinoma in the EPIC study.Integration and comparison of different genomic data for outcome prediction in cancer.Predicting dementia risk in primary care: development and validation of the Dementia Risk Score using routinely collected data.Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis.Use of the concordance index for predictors of censored survival data.Statistical evaluation of adding multiple risk factors improves Framingham stroke risk scoreReview and evaluation of performance measures for survival prediction models in external validation settings.Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.Concordance for prognostic models with competing risksOn hazard ratio estimators by proportional hazards models in matched-pair cohort studies.Graphical procedures for evaluating overall and subject-specific incremental values from new predictors with censored event time data.Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib.Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis.The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery.Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).Sample size estimation for time-dependent receiver operating characteristic.Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetesA leave-one-out cross-validation SAS macro for the identification of markers associated with survival.PREOP-Gallstones: A Prognostic Nomogram for the Management of Symptomatic Cholelithiasis in Older Patients.Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS).Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach.Assessing discriminative ability of risk models in clustered data.Multidimensional Prognostic Index predicts mortality and length of stay during hospitalization in the older patients: a multicenter prospective study.Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program.Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA.Unscheduled-return-visits after an emergency department (ED) attendance and clinical link between both visits in patients aged 75 years and over: a prospective observational study.survcomp: an R/Bioconductor package for performance assessment and comparison of survival models.A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer
P2860
Q26859166-749CD961-DF4C-47AA-A8A0-CB7DB654D2C8Q28488483-7BFD843C-3130-42F6-AA56-9FF0AEE2F976Q28546718-1CD2A8CC-61C7-4A35-899A-98D597E4240CQ30365539-0AB9371E-0F6B-47D2-9267-F4D0C5DF8FC6Q30572074-254BF89B-23E5-42CE-80EA-65175106EE38Q30670518-3A75BEAC-0E06-48B1-B225-B145D0CAE0A6Q30724002-F5C1CD85-BDD7-4CE2-84EB-B3D5B303AE45Q30727965-537DCBD5-2EB4-43C3-899C-6010D8F4CC8FQ30838620-8C0DC0D3-1FD3-4B9F-BDF4-7F853BFE178FQ30881367-115111D9-E5CC-47B7-92B6-0BAF86120914Q30977795-690B058F-8FB7-4FE8-B1CD-7A0FA160B270Q31013326-0E62FC00-CEE8-4435-A800-D63334AD092AQ31038971-6E31F3CA-59F8-4CDC-A6C6-A14DF5C255D4Q31089944-7771B0C6-5916-4D1F-9788-9146A5AEA32CQ31147068-61C2F311-0131-413D-9BF9-4404EC6C1E78Q33564681-01778DD9-49CA-42AB-A11C-5DDA2139E022Q33576899-17F2CEC7-D30C-43EC-92B7-B5E693D8C7A1Q33717226-F9E38CDF-9D9E-4F86-B028-0E08C9D64EF6Q33762612-E03DACFC-C961-4AC7-B386-F6F3911BB9C1Q33768459-B504C810-F936-4C23-8705-19C7865F82F7Q33876793-DF827061-9B10-40DF-9B3C-FEF26E81B518Q33882096-1856B29F-71DA-4F7B-A300-A351A6712EC5Q33889762-6A47B839-51CA-46BB-9C53-4E748438B0F7Q33984153-B51FF7DB-7884-4CF4-978D-D40299C610C3Q34039859-7E3EF2F5-61BE-4491-B4D9-2FD200E027FFQ34222867-8E8079A8-DBA9-495E-8D0C-91A1285BEC65Q34550775-428890F6-348A-4877-8580-478C02F5139FQ34765830-D4736B0C-74D6-4C3C-9F46-B8C4189AC45BQ35013993-48972C9A-2F29-4F06-8AC1-EE2C86F0EEEEQ35024142-0E6BFA2A-2502-4381-92CE-C872E0ADDBADQ35039868-148C2C65-75CA-4AF8-848B-7E7DB2AF1D85Q35040215-CFDD16FD-83BD-4BA4-BB3C-56819A53AA4EQ35085176-BE891427-E717-4CF5-A98D-97C8DD501AAEQ35152888-70AB2E26-71BD-4155-8F02-300E4C0680F5Q35159804-CC941488-E6E6-4056-9790-C065FB919B88Q35221326-A034FFBA-F0EE-47D5-A3C4-278FBB918111Q35326576-A0F70DF8-6F4F-4E67-8C65-9AF537077A6AQ35526651-7A73E850-0A5D-4030-9EC7-B423C491FBC4Q35546984-182D7504-1363-48DB-8ADE-5B69B5A308E2Q35584698-6610CC6E-CFA9-48C7-A78D-874A327CE107
P2860
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
On the C-statistics for evalua ...... s with censored survival data.
@ast
On the C-statistics for evalua ...... s with censored survival data.
@en
type
label
On the C-statistics for evalua ...... s with censored survival data.
@ast
On the C-statistics for evalua ...... s with censored survival data.
@en
prefLabel
On the C-statistics for evalua ...... s with censored survival data.
@ast
On the C-statistics for evalua ...... s with censored survival data.
@en
P2093
P2860
P356
P1476
On the C-statistics for evalua ...... s with censored survival data.
@en
P2093
Hajime Uno
Ralph B D'Agostino
Tianxi Cai
P2860
P304
P356
10.1002/SIM.4154
P407
P577
2011-01-13T00:00:00Z